Concepedia
Statistics
Publications
17
Citations
1.6K
H-Index
14
Active since
2004
Affiliations
University of Arizona(Current)
United States Military Academy
Clovis Oncology (United States)
Infinity Pharmaceuticals (United States)
Arizona Science Center
Matthew Labenski is an author at University of Arizona specializing in pharmacology, medicine, and enzyme inhibition.
Publications per year
2004–2024
Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Annette O. Walter, Robert Tjin Tham Sjin, Henry J. Haringsma et al. · Cancer Discovery · 2013 · 627 citations · Full text
Medicine, Oncology, Pharmacology +17
Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans
Erica Evans, Richland Tester, Sharon Aslanian et al. · Journal of Pharmacology and Experimental Therapeutics · 2013 · 219 citations
Medicine, Immunology, Pharmacology +17
Labeling Preferences of Diazirines with Protein Biomolecules
Alexander V. West, Giovanni Muncipinto, Hung‐Yi Wu et al. · Journal of the American Chemical Society · 2021 · 203 citations · Full text
Life Sciences, Biochemistry, Molecular Biology +15
A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis
Sylvie G. Bernier, Douglas Lazarus, Edward J. Clark et al. · Proceedings of the National Academy of Sciences · 2004 · 108 citations · Full text
Medicine, Pharmacology, Pharmacotherapy +17
Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine
Margit Hagel, Deqiang Niu, Thia St Martin et al. · Nature Chemical Biology · 2010 · 93 citations
Life Sciences, Biochemistry, Medicinal Chemistry +14
1–5 of 17